Avantor, Inc.

NYSE:AVTR

Medical - Instruments & Supplies

Healthcare
$15.37 +0.69%

+$0.07 today

Market cap
$10.41B
Beta
0.96
P/E (TTM)
-11.7
EPS (TTM)
-$0.81
52W Low $7.27High $15.93

Volume 5.94M

Average 9.44M

AVTR Other Non-Cash Items

Other non-cash adjustments that reconcile net income to operating cash flow.

Avantor, Inc.NYSE: AVTR

Other Non-Cash Items · Q2 FY2026 · quarter ended Jun 2026

Other non-cash items grows, but more slowly than its trailing trend

Q2 FY2026 other non-cash items of $24.9M rose 27.7% year over year, behind the +366.6% change in trailing-twelve-month other non-cash items. Sequentially, it rose 100.8% from the prior quarter. Over 3 fiscal years it compounded at +109.8% a year.

Context

  • Other non-cash items amounted to 13.6% of revenue in FY2025, up 8.8 pp from a year earlier.
  • Other non-cash items increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +27.7% toward the trailing-twelve-month pace of +366.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$24.9M+100.8% QoQ
Last fiscal yearDec 2025
$888.6M+374.4% YoY
LTMJun 2026
$870.3M+366.6% YoY
Other Non-Cash Items past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+27.7%——
1 year+374.4%——
3-year CAGR+109.8%——
5-year CAGR——
10-year CAGR——

Other Non-Cash Items history

USD · from the cash flow

Latest · FY2025
888.6M USD
Year-over-year change
+374.4%
4-year CAGR
+80.7%

Other Non-Cash Items vs competitors

How AVTR compares with its peers on the latest reported figures

  • Peers report in different currencies, so other non-cash items is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +366.6% is the 2nd highest of 9, against a peer median of +79.9%.
  • Other non-cash items amounts to 13.3% of revenue for AVTR, versus a peer median of 5.3%.
AVTR Competitors
Other Non-Cash Items for AVTR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DHRDanaher CorporationLTM Sep 2026$991M USD+24.7%+7.9%3.9%
AVTRAvantor, Inc.LTM Jun 2026$870.3M USD+366.6%+109.8%13.3%
CRLCharles River Laboratories International, Inc.LTM Jun 2026$579.04M USD+41.5%—14.5%
BIOBio-Rad Laboratories, Inc.LTM Jun 2026$495.7M USD+181.2%—19.1%
WSTWest Pharmaceutical Services, Inc.LTM Jun 2026$182M USD+1129.7%—5.5%
AZTAAzenta, Inc.LTM Sep 2026$156.85M USD+63.8%—25.2%
STVNStevanato Group S.p.A.LTM Jun 2026€16.97M EUR+96.0%—1.4%
RGENRepligen CorporationLTM Jun 2026$8.46M USD-42.5%-36.9%1.1%
BLFSBioLife Solutions, Inc.LTM Mar 2026$5.17M USD+155.9%-62.3%5.2%
Peer median (excluding AVTR) —+79.9%-36.9%5.3%

Competitors are the stored peer set for AVTR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income572.6M686.5M321.1M711.5M(530.2M)
Depreciation & Amortization379.2M405.5M402.3M405.5M410.2M
Deferred Income Tax(17.7M)(69.1M)(172.4M)(46.9M)7.7M
Stock-Based Compensation50.7M45.8M40.5M46.8M46.4M
Change in Working Capital(114.5M)(321.3M)16.6M47.7M(198.9M)
Accounts Receivables(111.8M)(45.2M)77M45.9M13.6M
Inventory(129.8M)(112.5M)30.3M(18.5M)(109.4M)
Accounts Payables64.9M15.6M(139.6M)59.6M42.4M
Other Working Capital62.2M(179.2M)48.9M(39.3M)(145.5M)
Other Non-Cash Items83.3M96.2M261.9M(323.8M)888.6M
Operating Cash Flow953.6M843.6M870M840.8M623.8M
Capital Expenditures(111.1M)(133.4M)(146.4M)(148.8M)(128.8M)
Acquisitions (Net)(4.01B)(20.2M)000
Purchases of Investments00000
Sales of Investments042.5M000
Other Investing Activities3.5M1.5M2.7M587.7M(1.7M)
Investing Cash Flow(4.12B)(109.6M)(143.7M)438.9M(130.5M)
Debt Repayment2.3B(620.4M)(846M)(1.34B)(318.7M)
Common Stock Issued967M0005.1M
Common Stock Repurchased(25.8M)(13.2M)(13.7M)(8.6M)(80.7M)
Dividends Paid(64.6M)(32.4M)000
Other Financing Activities41.9M17.3M16M69.2M(15.1M)
Financing Cash Flow3.22B(648.7M)(843.7M)(1.28B)(409.4M)
Effect of Forex Changes(13.2M)(15.5M)8.2M(21.5M)19.7M
Net Change in Cash37.9M69.8M(109.2M)(23M)103.6M
Free Cash Flow842.5M710.2M723.6M692M495M

Avantor, Inc.

NYSE:AVTR

Intrinsic Alpha fair value

Locked

Current Price

$15.37

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.